Document is current

Article History

First Online: 24 October 2024

Disclosures

: Shaliz Aflatooni, Dr. Michelle M. Dugan, Aleena Boby, Helana Ghali, Dr. Danielle K. DePalo, and Dr. Syeda Mahrukh Hussnain Naqvi have no conflicts of interest or financial ties to disclose. Dr. Jonathan S. Zager has received payments from Delcath Systems – Medical Advisory Board. He has consulting agreements with Philogen, Merit Medical, Castle Biosciences, and Merck. His department receives research funding from Philogen, SWOG, Delcath Systems, and Provectus. Moffitt Cancer Center has licensed Intellectual Property (IP) related to the proliferation and expansion of tumor infiltrating lymphocytes (TILs) to Iovance Biotherapeutics. Dr. Mullinax (JEM) is an inventor on such Intellectual Property. JEM participates in sponsored research agreements with Iovance Biotherapeutics, Intellia Therapeutics, and SQZ Biotech that are not related to this research. JEM has received research support that is not related to this research from the following entities: NIH-NCI (K08CA252642), Ocala Royal Dames, and V Foundation. Dr. Mullinax has received ad hoc consulting fees from Merit Medical and Iovance Biotherapeutics. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.